Malignant Pleural Mesothelioma

News alerts, weekly reports and conference planners

Related cancers:

‹

Mesothelioma (88)

›

No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + raltitrexed Sensitive: A2 - Guideline carboplatin + raltitrexed Sensitive : A2	carboplatin + raltitrexed Sensitive: A2 - Guideline carboplatin + raltitrexed Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
NF2 deletion	Malignant Pleural Mesothelioma	NF2 deletion	Malignant Pleural Mesothelioma	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B	IK-930 Sensitive: B - Late Trials IK-930 Sensitive : B
PD-L1 expression	Malignant Pleural Mesothelioma	PD-L1 expression	Malignant Pleural Mesothelioma	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1	nivolumab Sensitive: C1 - Off-label nivolumab Sensitive : C1
WT1 expression	Malignant Pleural Mesothelioma	WT1 expression	Malignant Pleural Mesothelioma	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials nivolumab + galinpepimut-S Sensitive : C3	nivolumab + galinpepimut-S Sensitive: C3 – Early Trials nivolumab + galinpepimut-S Sensitive : C3
TMB-L	Malignant Pleural Mesothelioma	TMB-L	Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
TMB-L	Malignant Pleural Mesothelioma	TMB-L	Malignant Pleural Mesothelioma	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
PD-L1 underexpression	Malignant Pleural Mesothelioma	PD-L1 underexpression	Malignant Pleural Mesothelioma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
ERCC1 expression	Malignant Pleural Mesothelioma	ERCC1 expression	Malignant Pleural Mesothelioma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
RRM1 expression	Malignant Pleural Mesothelioma	RRM1 expression	Malignant Pleural Mesothelioma	Sensitive: C3 – Early Trials Sensitive : C3	Sensitive: C3 – Early Trials Sensitive : C3
MSLN overexpression	Malignant Pleural Mesothelioma	MSLN overexpression	Malignant Pleural Mesothelioma	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3	TC-210 Sensitive: C3 – Early Trials TC-210 Sensitive : C3
ASS1 mutation	Malignant Pleural Mesothelioma	ASS1 mutation	Malignant Pleural Mesothelioma	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials cisplatin + pemetrexed + pegargiminase Sensitive : C3	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials cisplatin + pemetrexed + pegargiminase Sensitive : C3
BAP1 deletion	Malignant Pleural Mesothelioma	BAP1 deletion	Malignant Pleural Mesothelioma	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
BAP1 deletion	Malignant Pleural Mesothelioma	BAP1 deletion	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PD-L1 overexpression	Malignant Pleural Mesothelioma	PD-L1 overexpression	Malignant Pleural Mesothelioma	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
EML4-ALK I1171N + EML4-ALK L1196M	Malignant Pleural Mesothelioma	EML4-ALK I1171N + EML4-ALK L1196M	Malignant Pleural Mesothelioma	alectinib Resistant: C4 – Case Studies alectinib Resistant : C4	alectinib Resistant: C4 – Case Studies alectinib Resistant : C4
CD74-ROS1 fusion	Malignant Pleural Mesothelioma	CD74-ROS1 fusion	Malignant Pleural Mesothelioma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion	Malignant Pleural Mesothelioma	MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion	Malignant Pleural Mesothelioma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
MTAP deletion + PIK3CA mutation	Malignant Pleural Mesothelioma	MTAP deletion + PIK3CA mutation	Malignant Pleural Mesothelioma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
BRCA2 mutation	Malignant Pleural Mesothelioma	BRCA2 mutation	Malignant Pleural Mesothelioma	niraparib + dostarlimab-gxly Sensitive: C4 – Case Studies niraparib + dostarlimab-gxly Sensitive : C4	niraparib + dostarlimab-gxly Sensitive: C4 – Case Studies niraparib + dostarlimab-gxly Sensitive : C4

Malignant Pleural Mesothelioma

Associations(33)

Associations
(33)